𖣂📈 The next evolution: XEN+PV1 interviews, AVE:101, GRE→1+1=3?

HOMODEUS RESEARCH WEEKLY BRIEF · 13 June 2026 Video killed the PDF star… A couple of webinars this week with Xenitra (ASX:XEN) and Provaris (ASX:PV1) on two very different but fascinating businesses. On one hand we have an FMCG turnaround story with a tokenised loyalty scheme which also doubles as anti-counterfeit measures into the China market. And on the other a critical infrastructure play into energy transition. ASX:XEN ASX:PV1 Highlight of the week: Avecho foundation research | GreenTech Metals (ASX:GRE) opinion piece Feeling generous? I’ve just signed up to the push-up challenge this year. With all my donations going to support headspace, Australia’s National Youth Mental Health Foundation. You donate here . NEWS THIS WEEK Avecho Biotechnology (ASX:AVE) is approaching Phase III result interim analysis of its pivotal insomnia trial for TPM-enhanced CBD capsules (late-June 2026). Source: Homodeus research GreenTech Metals (ASX:GRE) Reinterpreting Two Historical Deposits to Bring On A New Copper Hub. Both deposits have been known for decades, but at today's prices, both have bulk tonnage mining potential. Combined into a single hub and spoke operation, the case becomes…